News

The effect of a carbapenem on VPA is significant and may result in reduced efficacy and increased seizure activity. Because of the mechanism of this interaction, increasing the dose of the VPA will unlikely achieve therapeutic plasma concentrations.

A new study suggests patients with disorganized retinal inner layers see lesser levels of visual acuity improvement after therapy.

These non-critical items are often used on multiple patients, and a lack of knowledge about proper cleaning and disinfection could contribute to the spread of C difficile.

People who are addicted to drugs face a higher risk of contracting HCV. Yet, a new study suggests the majority teens who are addicted to opioids don’t get screened for the virus.

Only about half of people living with HIV who were released from prison or jail remained in HIV care 1-2 years after release.

Yutiq, a fluocinolone acetonide intravitreal implant, is indicated for the treatment of chronic non-infectious uveitis that affects the posterior segment of the eye.

A comparison of patients in a pair of European-based studies tracking adherence to the diet found those eating healthier were significantly less likely to develop late-stage AMD.

A pair of new studies suggests combining 2 new broadly neutralizing antibodies might be an effective way to achieve long-term HIV viral suppression without the use of antiretroviral therapy.

Active-duty military personnel report a deadly opioid overdose rate just one-fourth of the general population. What does the military do with its patient registries that could be repeatable in public health?

The FDA has granted a priority review to combination therapy, ibrutinib/obinutuzumab, for the treatment of previously untreated adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL).

Individuals with hepatitis C infection who use cannabis were also found to have lower total healthcare costs than non-users.

Antibiotic use is believed to be a C difficile infection risk factor for inflammatory bowel disease patients.

The IL-4 and -13 inhibitor antibody also reported improved outcomes in patients with comorbid asthma.

First approved in 2015, the levonorgestrel-releasing Liletta IUD is now approved for contraceptive use for up to 5 years.

Patients receiving valbenazine for tardive dyskinesia reported high levels of satisfaction, even after up to 2 years of treatment.

Allergic rhinitis involves the immune system, which responds to allergens by releasing histamine, causing inflammatory symptoms in the nose, throat, and eyes—which can also worsen asthma conditions.

Long-term treatment with valbenazine improved tardive dyskinesia symptoms over 48 weeks.

New research suggests that the choice of a direct-acting antiviral regimen does not appear to affect liver cancer risk in patients with HCV.

New research finds a mobile-optimized HIV-prevention program works, but its impact dissipates with time.

Results connecting breathlessness catastrophizing with reduced quality of life also have implications for populations with asthma or COPD.

Clinicians should encourage natural light exposure to reduce the risk of postpartum depression in women with third trimesters in the fall, study suggests.

The optimal treatment of submassive pulmonary embolism (PE) remains controversial, despite growing evidence to support a role for catheter-directed therapy in carefully selected patients.

Investigators in the United Kingdom have found that a simple blood test reveals the earliest signs of Huntington’s disease, and may help scientists working on developing new therapeutics for the genetic disease.

Efficacy was superior to placebo regardless of patient BMI, supporting adequacy of recommended dosing regimens for overweight and obese patients.

Antipsychotic dose reductions can increase mental illness and all-cause hospitalizations, but the effects on tardive dyskinesia were unclear.

The ID CORE XT is the second molecular assay approved for use in transfusion medicine and the first to report results as genotypes.

Rivaroxaban (Xarelto) is now indicated to reduce the risk of major cardiovascular events in patients with chronic coronary artery disease or peripheral artery disease.

Palynziq is specifically intended for use by patients with PKU over the age of 18 who have blood Phe levels at or above 600 μmol/L while following their current therapies.